ClinicalTrials.gg
TerminatedNCT02534038Updated May 13, 2026Results posted

Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

A Phase 2 interventional study of AVP-786 and Placebo in Disinhibition Syndrome, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 1 site in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated prematurely because of difficulty with recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Study summary

Treatment of disinhibition syndrome in participants with Neurodegenerative Disorder.

Read the detailed description

Eligible participants for this study must have a diagnosis of Neurodegenerative Disorder and must exhibit disinhibition syndrome of sufficient severity to warrant treatment.

This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study consisting of two 6-week treatment periods.

Approximately 12 participants will be enrolled at approximately 2 centers in the United States.

Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants will be randomized into the study.

02

Conditions studied

  • Disinhibition Syndrome

Keywords

  • Disinhibition
03

In context

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of a Neurodegenerative Disorder including frontotemporal dementia, Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), dementia with Lewy bodies (DBL), vascular cognitive disorders, or Huntington's disease, at least 3 months prior to Baseline
  • The participant has behavior from 2 of the 3 categories of disinhibited behavior from the definition of the behavioral variant of frontotemporal dementia
  • The behavioral changes are not due to a pre-existing major psychiatric disorder (e.g., schizophrenia, bipolar disease, etc.) and are not due to the direct effect of systemic illness, drug action, or substance use
  • Disinhibition scale score of ≥4 on the 3 core disinhibition items of the Frontal Behavioral Inventory (FBI) at Screening and Baseline

Exclusion criteria

Exclusion Criteria:

  • Participants with symptoms of disinhibition that is not secondary to Neurodegenerative Disorders
  • Participants with myasthenia gravis
  • Participants with co-existent or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., [except skin basal-cell carcinoma or untreated prostate cancer], poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1 participant (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo drug to be taken twice a day for 6 weeks

    Drug: Placebo

  • Active comparator
    AVP-786

    Participants randomized to AVP-786 will take one dose of AVP-786 once a day and one dose of placebo once a day for the first 7 days; from day 8, participants will receive AVP-786 twice a day for 5 weeks.

    Drug: AVP-786

Interventions

  • DrugAVP-786

    Drug pages: Deudextromethorphan · Quinidine

    d6-DM/Q

    Also known as: Deuterated (d6)-dextromethorphan (DM)/Quinidine (Q)

  • DrugPlacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Disinhibition Domain of the Neuropsychiatric Inventory (NPI)

    Time frame: Baseline; Week 6, Week 8, and Week 14

Secondary outcomes

  1. Change From Baseline for the Total NPI Score

    Time frame: Baseline; Week 6, Week 8, and Week 14

  2. Change From Baseline for the NPI Total Caregiver Distress

    Time frame: Baseline; Week 6, Week 8, and Week 14

  3. Change From Baseline for the NPI Disinhibition Domain Caregiver Distress

    Time frame: Baseline; Week 1, Week 3, Week 6, Week 8, Week 9, Week 11, and Week 14

  4. Change From Baseline for the Frontal Behavioral Inventory (FBI) Total Score

    Time frame: Baseline; Week 1, Week 3, Week 6, Week 8, Week 9, Week 11, and Week 14

  5. Change From Baseline for the FBI Disinhibition Domain Score

    Time frame: Baseline; Week 1, Week 3, Week 6, Week 9, Week 11, and Week 14

  6. Change From the First Assessment for the Modified Clinical Global Impression of Change (mCGIC) Scale

    Time frame: Week 3, Week 6, Week 11, and Week 14

  7. Change From the First Assessment for the Patient Global Impression of Change (PGIC) Scale

    Time frame: Week 3, Week 6, Week 11, and Week 14

  8. Change From Baseline for the Quality of Relationships (QoR) Scale

    Time frame: Baseline; Week 6, Week 8, and Week 14

  9. Change From Baseline for the Quality of Life (QoL) Scale

    Time frame: Baseline; Week 6, Week 8, and Week 14

  10. Change From Baseline for the Interpersonal Reactivity Index (IRI)

    Time frame: Baseline; Week 6, Week 8, and Week 14

  11. Change From Baseline for the Center for Neurologic Study-Lability Scale (CNS-LS)

    Time frame: Baseline; Week 6, Week 8, and Week 14

  12. Change From Baseline for the Mini-Mental State Examination (MMSE)

    Time frame: Baseline; Week 6, Week 8, and Week 14

  13. Change From Baseline for the Cornell Scale for Depression in Dementia (CSDD)

    Time frame: Baseline; Week 6, Week 8, and Week 14

  14. Change From Baseline for the Stroop Color and Word Task

    Time frame: Baseline; Week 6, Week 8, and Week 14

07

Results

Posted Oct 26, 2020
Limitations and caveats
The study was terminated due to lack of enrollment.

Participant flow

Period 1 (6 Weeks)
Participant flow — Period 1 (6 Weeks)
MilestoneAVP-786; PlaceboPlacebo; AVP-786
Started10
Completed10
Not completed00
Period 2 (6 Weeks)
Participant flow — Period 2 (6 Weeks)
MilestoneAVP-786; PlaceboPlacebo; AVP-786
Started10
Completed10
Not completed00

Outcome measures

PrimaryChange From Baseline in the Disinhibition Domain of the Neuropsychiatric Inventory (NPI)
Time frame:
Baseline; Week 6, Week 8, and Week 14

No measurements were reported for this outcome.

SecondaryChange From Baseline for the Total NPI Score
Time frame:
Baseline; Week 6, Week 8, and Week 14

No measurements were reported for this outcome.

SecondaryChange From Baseline for the NPI Total Caregiver Distress
Time frame:
Baseline; Week 6, Week 8, and Week 14

No measurements were reported for this outcome.

SecondaryChange From Baseline for the NPI Disinhibition Domain Caregiver Distress
Time frame:
Baseline; Week 1, Week 3, Week 6, Week 8, Week 9, Week 11, and Week 14

No measurements were reported for this outcome.

SecondaryChange From Baseline for the Frontal Behavioral Inventory (FBI) Total Score
Time frame:
Baseline; Week 1, Week 3, Week 6, Week 8, Week 9, Week 11, and Week 14

No measurements were reported for this outcome.

SecondaryChange From Baseline for the FBI Disinhibition Domain Score
Time frame:
Baseline; Week 1, Week 3, Week 6, Week 9, Week 11, and Week 14

No measurements were reported for this outcome.

SecondaryChange From the First Assessment for the Modified Clinical Global Impression of Change (mCGIC) Scale
Time frame:
Week 3, Week 6, Week 11, and Week 14

No measurements were reported for this outcome.

SecondaryChange From the First Assessment for the Patient Global Impression of Change (PGIC) Scale
Time frame:
Week 3, Week 6, Week 11, and Week 14

No measurements were reported for this outcome.

SecondaryChange From Baseline for the Quality of Relationships (QoR) Scale
Time frame:
Baseline; Week 6, Week 8, and Week 14

No measurements were reported for this outcome.

SecondaryChange From Baseline for the Quality of Life (QoL) Scale
Time frame:
Baseline; Week 6, Week 8, and Week 14

No measurements were reported for this outcome.

SecondaryChange From Baseline for the Interpersonal Reactivity Index (IRI)
Time frame:
Baseline; Week 6, Week 8, and Week 14

No measurements were reported for this outcome.

SecondaryChange From Baseline for the Center for Neurologic Study-Lability Scale (CNS-LS)
Time frame:
Baseline; Week 6, Week 8, and Week 14

No measurements were reported for this outcome.

SecondaryChange From Baseline for the Mini-Mental State Examination (MMSE)
Time frame:
Baseline; Week 6, Week 8, and Week 14

No measurements were reported for this outcome.

SecondaryChange From Baseline for the Cornell Scale for Depression in Dementia (CSDD)
Time frame:
Baseline; Week 6, Week 8, and Week 14

No measurements were reported for this outcome.

SecondaryChange From Baseline for the Stroop Color and Word Task
Time frame:
Baseline; Week 6, Week 8, and Week 14

No measurements were reported for this outcome.

Adverse events

Collected over up to 22 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/1 (0%)0/1 (0%)0/1 (0%)
AVP-7860/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventPlaceboAVP-786
Blood bilirubin increasedInvestigations0/11/1
Blood creatine phosphokinase increasedInvestigations0/11/1

Baseline characteristics

A limited number of participants were enrolled prior to study termination.

Age, Categorical
Age, Categorical(Participants)AVP-786; PlaceboPlacebo; AVP-786Total
<=18 years0—0
Between 18 and 65 years0—0
>=65 years1—1
Sex: Female, Male
Sex: Female, Male(Participants)AVP-786; PlaceboPlacebo; AVP-786Total
FemaleNA—NA
MaleNA—NA
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AVP-786; PlaceboPlacebo; AVP-786Total
American Indian or Alaska NativeNA—NA
AsianNA—NA
Native Hawaiian or Other Pacific IslanderNA—NA
Black or African AmericanNA—NA
WhiteNA—NA
More than one raceNA—NA
Unknown or Not ReportedNA—NA
08

Study locations

1 site
  • Cleveland Clinic Lou Ruvo Center for Brain Health
    Las Vegas, Nevada 89106, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Oct 2017, 22 months.

Results were first posted in Oct 2020, 3 years after primary completion. A results delay was requested in Oct 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2015
First posted
Aug 27, 2015
StartActual
Dec 1, 2015
Primary completionActual
Oct 3, 2017
CompletionActual
Oct 3, 2017
Results delay requested
Oct 2, 2018
Results first posted
Oct 26, 2020
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02534038
Responsible party
Sponsor
First posted
Aug 27, 2015
Start date
Dec 1, 2015
Primary completion
Oct 3, 2017
Completion
Oct 3, 2017
Results posted
Oct 26, 2020
Last update
May 13, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Deudextromethorphan · Quinidine

Start the discussion